Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

QNCX

Quince Therapeutics Inc

Dec 10 • 04:00PM ET

1.97

Dollar change -0.07
Percentage change -3.43	%

Healthcare • Biotechnology • USA • NASD

Peers: IMCR BEAM NTLA CRSP EDIT VERV PRME RNA MGTX RPRX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.25	Insider Own	25.87%	Shs Outstand	43.28M	Perf Week	-8.80%
Market Cap	86.68M	Forward P/E	-	EPS next Y	-	Insider Trans	2.17%	Shs Float	32.62M	Perf Month	15.88%
Income	-53.26M	PEG	-	EPS next Q	-0.18	Inst Own	11.40%	Short Float	5.49%	Perf Quarter	168.03%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-12.96%	Short Ratio	3.23	Perf Half Y	150.00%
Book/sh	1.04	P/B	1.90	EPS next Y	-	ROA	-50.27%	Short Interest	1.79M	Perf Year	104.15%
Cash/sh	1.09	P/C	1.81	EPS next 5Y	18.30%	ROE	-83.18%	52W Range	0.51 - 2.45	Perf YTD	87.62%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.64%	ROI	-88.36%	52W High	-19.59%	Beta	0.63
Dividend TTM	-	Quick Ratio	9.53	Sales past 5Y	0.00%	Gross Margin	-	52W Low	285.07%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	9.53	EPS Y/Y TTM	-60.02%	Oper. Margin	-	RSI (14)	56.96	Volatility	17.70% 14.77%
Employees	32	Debt/Eq	0.34	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	9.67
Option/Short	Yes / Yes	LT Debt/Eq	0.34	EPS Q/Q	14.23%	Payout	-	Rel Volume	0.27	Prev Close	2.04
Sales Surprise	-	EPS Surprise	24.99%	Sales Q/Q	-	Earnings	Nov 13 AMC	Avg Volume	555.09K	Price	1.97
SMA20	2.05%	SMA50	40.74%	SMA200	96.84%	Trades		Volume	151,834	Change	-3.43%

Nov-13-24 04:05PM	Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (Business Wire) -5.36% +19.50%
Nov-12-24 04:05PM	Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research (Business Wire)
Nov-11-24 04:05PM	Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting (Business Wire)
Oct-14-24 04:05PM	Quince Therapeutics to Participate at Upcoming Investor Conferences (Business Wire) +13.83%
Sep-03-24 04:05PM	Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
04:12AM	Loading…
Aug-16-24 04:12AM	Quince reports data from Phase III Ataxia-Telangiectasia treatment trial (Clinical Trials Arena)
Aug-15-24 07:00AM	Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) (Business Wire)
Aug-13-24 04:05PM	Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (Business Wire) -16.54%
Jun-26-24 07:13AM	Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial (Clinical Trials Arena)
Jun-25-24 07:00AM	Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia (Business Wire)
Jun-04-24 07:15AM	FDA fast tracks Quince Therapeutics rare ataxia drug EryDex (Pharmaceutical Technology)
Jun-03-24 07:00AM	Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System (Business Wire) +5.66%
May-13-24 01:53PM	QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024 (InvestorPlace)
07:00AM	Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (Business Wire)
May-06-24 04:05PM	Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference (Business Wire)
09:53AM	Loading…
Apr-02-24 09:53AM	QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Apr-01-24 07:00AM	Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results (Business Wire)
Feb-22-24 07:00AM	Quince Therapeutics Launches Scientific Advisory Board (Business Wire)
Feb-15-24 07:00AM	Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors (Business Wire)
Feb-07-24 04:05PM	Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-04-24 04:05PM	Quince Therapeutics to Participate at Investor Events in January 2024 (Business Wire)
Dec-04-23 07:21AM	10 Best Debt Free Penny Stocks To Buy Now (Insider Monkey)
Oct-23-23 07:00AM	Quince Therapeutics Completes Acquisition of EryDel S.p.A. (Business Wire)
Sep-28-23 04:05PM	U.S. FDA Partial Clinical Hold Lifted on IND for EryDels Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia (Business Wire)
Sep-06-23 07:00AM	Quince Therapeutics Appoints Dr. Charles S. Ryan as President (Business Wire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-10-23 04:05PM	Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023 (Business Wire)
Jul-24-23 07:00AM	Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity (Business Wire) -27.22%
Jul-13-23 08:00AM	Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc. (ACCESSWIRE) +7.84%
Jun-06-23 08:00AM	Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value (ACCESSWIRE)
07:00AM	Loading…
Apr-11-23 07:00AM	Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital (Business Wire)
Apr-06-23 04:05PM	Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor (Business Wire) -7.32%
Apr-05-23 04:05PM	Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan (Business Wire) -6.70%
Mar-22-23 05:00AM	Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital (Business Wire)
Mar-21-23 08:00AM	Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc. (ACCESSWIRE) +71.10%
Jan-30-23 04:05PM	Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023 (Business Wire) -7.41%
Jan-27-23 08:00AM	Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals (Business Wire) +33.66%
Nov-21-22 09:09AM	We Think Quince Therapeutics (NASDAQ:QNCX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-16-22 08:00AM	Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury (Business Wire) -6.83%
Sep-12-22 08:00AM	Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications (Business Wire)
Aug-30-22 04:05PM	Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures (Business Wire)
Aug-25-22 04:05PM	Quince Therapeutics to Present at Upcoming Scientific Meetings (Business Wire)
Aug-04-22 08:00AM	Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022 (Business Wire)
Aug-01-22 08:00AM	Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name (Business Wire)

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient's biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thye Dirk	CEO AND CHIEF MEDICAL OFFICER	Aug 30 '24	Buy	0.70	77,000	53,900	843,941	Sep 03 05:38 PM
Thye Dirk	CEO AND CHIEF MEDICAL OFFICER	Aug 29 '24	Buy	0.69	77,500	53,475	766,941	Sep 03 05:38 PM
Ryan Charles S.	PRESIDENT	Aug 20 '24	Buy	0.65	48,387	31,452	122,461	Aug 22 05:51 PM
Hannah Brendan	CHIEF BUSINESS OFFICER AND COO	Aug 21 '24	Buy	0.63	30,845	19,337	296,540	Aug 21 06:38 PM
Hannah Brendan	CHIEF BUSINESS OFFICER AND COO	Aug 20 '24	Buy	0.60	5,924	3,579	265,695	Aug 21 06:38 PM
Hannah Brendan	CHIEF BUSINESS OFFICER AND COO	Aug 19 '24	Buy	0.58	2,155	1,250	259,771	Aug 21 06:38 PM
Hannah Brendan	CHIEF BUSINESS OFFICER AND COO	Jun 04 '24	Option Exercise	0.55	56,061	30,834	257,616	Jun 05 02:37 PM
Thye Dirk	CHIEF EXECUTIVE OFFICER	Jan 16 '24	Option Exercise	0.79	240,530	190,791	689,441	Jan 17 04:48 PM
Lamond David	Director	Dec 14 '23	Buy	1.04	22,627	23,532	2,347,545	Dec 14 06:21 PM
Lamond David	Director	Dec 12 '23	Buy	1.02	22,327	22,774	2,302,291	Dec 14 06:21 PM
Lamond David	Director	Dec 13 '23	Buy	1.00	22,627	22,627	2,324,918	Dec 14 06:21 PM
Lamond David	Director	Dec 12 '23	Buy	1.00	300	300	2,279,964	Dec 14 06:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QNCX

Quince Therapeutics Inc

Upgrade your FINVIZ experience